VC Playbook
Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.
Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.
For biotech CEOs navigating today’s capital crunch, understanding what sophisticated investors actually look for can mean the difference between a successful raise and months of rejected pitches.
Investors and healthcare philanthropists have launched a new women’s health fund – aiming to be the largest of its kind – with an ambitious goal to not just finance innovation, but to build a sustainable market around it.
ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.
Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing.
Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma.
Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.
Startup financing may be hard to come by, but now is not the time to ask for less cash.
VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.
VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”
Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.
Created by Steve Lehmann, director of venture operations at Portal Innovations, Stargaze is an artificial intelligence platform that maps the structure of biotechnology innovation and uses that knowledge to identify fruitful startups.
Biomedical engineering graduate Cécile Dupont has for the past 12 years helped healthcare technology businesses develop disruptive solutions that positively impact patients’ lives. The current chapter of her career opened in 2017 when she joined Sofinnova MD Start, the early-stage medtech incubator of VC investor Sofinnova Partners, where she is a partner.